Written By

CAS Science Team

Download Whitepaper

Chemical Inhibitors to RAS Oncoproteins

Around one in every five human cancers have at least one form of RAS mutation (K-RAS, H-RAS, and N-RAS), making RAS the most frequently mutated gene family in human cancers.  Historically, these elusive RAS proteins have been called "undruggable", until a recent breakthrough from AmGen with the FDA’s approval of the anti-cancer drug sotorasib which targets a specific mutation, G12C, in the protein K-RAS.

Not surprisingly, there has been significant activity in this space recently and CAS provides a unique view into this landscape of emerging science in our latest white paper - "Chemical Inhibitors to RAS Oncoproteins: Current Landscape and Future Opportunities".

RAS Inhibitors white paper cover

  Complete the form below to download the white paper.

Read the related CAS Blog - "Emerging trends in targeting "undruggable" RAS proteins for cancer treatment"


Download the Whitepaper

Your privacy is important to CAS. More detail about how we use your information is in our privacy policy.